

A randomised, placebo controlled study of alfuzosin in patients undergoing trial without catheter following admission with acute urinary retention

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 21/02/2020	Condition category Signs and Symptoms	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr T Shah

Contact details
Urology Department
St. Luke's Hospital
Little Horton Lane
Bradford
United Kingdom
BD5 0NA

Additional identifiers

Protocol serial number
N0050072990

Study information

Scientific Title

A randomised, placebo controlled study of alfuzosin in patients undergoing trial without catheter following admission with acute urinary retention

Study objectives

To evaluate the role of an alpha-1 adrenoceptor antagonist in the treatment of acute urinary retention. To test the hypothesis that oral alfuzosin will increase the proportion of men in acute urinary retention who void after trial without catheter (AVR).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised placebo-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Signs and Symptoms: Acute urinary retention

Interventions

Randomised, placebo-controlled study at two centres. The aim of the study is to evaluate the effectiveness of alpha-adrenergic blocker alfuzosin SR 5 mg given to patients in acute urinary retention prior to trial without catheter (TWOC). If successful it would reduce the number of operative treatments for patients with bladder outlet obstruction due to benign prostatic hyperplasia (BPH).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Alfuzosin

Primary outcome(s)

Successful outcome will be measured in terms of spontaneous voiding

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/12/2000

Eligibility

Key inclusion criteria

Patients with acute urinary retention who meet inclusion criteria

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Male

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1998

Date of final enrolment

31/12/2000

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

St. Luke's Hospital

Bradford

United Kingdom

BD5 0NA

Sponsor information

Organisation

Department of Health (UK)

Funder(s)

Funder type

Industry

Funder Name

Loxex Synthelabo Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2002		Yes	No